https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24196 Wed 18 Aug 2021 08:22:06 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17016 Wed 11 Apr 2018 17:19:33 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18142 Wed 11 Apr 2018 17:16:54 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18243 Wed 11 Apr 2018 16:28:32 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22168 -/-) BALB/c mice were intranasally sensitised and challenged with HDM prior to infection with RV1B. In some experiments, mice were administered recombinant IFN or adoptively transferred with plasmacytoid dendritic cells (pDC). Results: Allergic Tlr7^-/- mice displayed impaired IFN release upon RV1B infection, increased virus replication and exaggerated eosinophilic inflammation and airways hyper reactivity. Treatment with exogenous IFN or adoptive transfer of TLR7-competent pDCs blocked these exaggerated inflammatory responses and boosted IFNγ release in the absence of host TLR7 signalling. TLR7 expression in the lungs was suppressed by allergic inflammation and by interleukin (IL)-5-induced eosinophilia in the absence of allergy. Subjects with moderate-to-severe asthma and eosinophilic but not neutrophilic airways inflammation, despite inhaled steroids, showed reduced TLR7 and IFNλ2/3 expression in endobronchial biopsies. Furthermore, TLR7 expression inversely correlated with percentage of sputum eosinophils. Conclusions: This implicates IL-5-induced airways eosinophilia as a negative regulator of TLR7 expression and antiviral responses, which provides a molecular mechanism underpinning the effect of eosinophil-targeting treatments for the prevention of asthma exacerbations.]]> Wed 11 Apr 2018 15:36:21 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21399 Wed 11 Apr 2018 15:17:09 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14469 Wed 11 Apr 2018 15:06:10 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15734 Wed 11 Apr 2018 15:04:13 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24019 Wed 11 Apr 2018 14:57:15 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15733 Wed 11 Apr 2018 14:55:40 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:11806 Wed 11 Apr 2018 14:52:14 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18673 Wed 11 Apr 2018 14:31:33 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17670 Wed 11 Apr 2018 14:20:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22667 Wed 11 Apr 2018 14:18:05 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21269 Wed 11 Apr 2018 14:00:25 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22634 Wed 11 Apr 2018 13:56:06 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19104 Wed 11 Apr 2018 13:29:44 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15731 Wed 11 Apr 2018 13:29:25 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13535 Wed 11 Apr 2018 13:23:17 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21012 60 Gy) with curative intent, will be recruited from radiotherapy departments at 5 Australian sites. Assessments will be conducted at 4 time points (first and final week of radiotherapy, 4 and 12 weeks postradiotherapy). The primary outcome will be a nutritional status assessment. ETHICS AND DISSEMINATION: Ethics approval from all relevant bodies has been granted. Study findings will be disseminated widely through peer-reviewed publications and conference presentations.]]> Wed 11 Apr 2018 12:47:57 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22636 Wed 11 Apr 2018 12:41:43 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21261 Wed 11 Apr 2018 12:22:40 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:3581 Wed 11 Apr 2018 12:14:02 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15294 Wed 11 Apr 2018 12:03:41 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23941 Wed 11 Apr 2018 11:33:41 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15739 Wed 11 Apr 2018 11:30:37 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22650 Wed 11 Apr 2018 11:14:14 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21224 w1 there have been some significant developments in terms of synthesis of existing evidence, as well as emerging therapies. We therefore summarise recent systematic reviews, meta-analyses, and randomised controlled trials in order to provide a general update as to how to effectively identify and manage this disorder.]]> Wed 11 Apr 2018 11:11:00 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26985 Wed 11 Apr 2018 11:05:57 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26162 Wed 11 Apr 2018 11:01:03 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24174 Wed 11 Apr 2018 10:48:24 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15598 Wed 11 Apr 2018 10:37:55 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17208 Wed 11 Apr 2018 10:35:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15730 Wed 11 Apr 2018 10:28:14 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25128 Wed 11 Apr 2018 10:21:32 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14543 Wed 11 Apr 2018 10:14:57 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24202 Wed 11 Apr 2018 09:54:59 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15729 Wed 11 Apr 2018 09:44:30 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13542 Wed 11 Apr 2018 09:42:40 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20668 Wed 11 Apr 2018 09:35:51 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17059 Wed 11 Apr 2018 09:27:31 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13928 Wed 11 Apr 2018 09:19:33 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28233 Wed 04 Sep 2019 10:37:52 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27763 Tue 19 Jun 2018 12:29:06 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20672 Tue 15 Sep 2015 09:41:54 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19639 1000(decisive), for both). However, there was decisive evidence toward negative Likert responses for the domains ‘Staffing and management’ (99.9%, BF>1000 (decisive)) and ‘Team working’ (99.3%, BF=132 (decisive)). Significant differences also emerged in favour of smaller hospitals for ‘Teamwork’ (96.2%, BF=26 (very strong)), clinical pharmacists (n=51) versus technicians (n=21) for ‘Perceptions of the causes of incidents/reporting’, ‘Teamwork’ and ‘Commitment to patient safety and education’ (99.9%, BF>1000 (decisive), for all). Also for pharmacists affiliated with a professional association (n=54) compared with all staff without an affiliation (n=43) (99.9%, BF>1000 (decisive)). Conclusions: Our findings identify important influences on the patient safety culture of hospital pharmacy, including the role of hospital type, pharmacy staff group and membership with professional-advocacy groups. A better understanding of the factors which drive these differences is necessary for pharmacy services to better embrace safety improvement initiatives.]]> Tue 11 Aug 2015 11:46:49 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18670 Tue 05 Mar 2019 09:27:51 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24160 Thu 30 Mar 2023 17:25:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25846 Thu 28 Oct 2021 12:37:11 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:9301 Sat 24 Mar 2018 08:41:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:9302 Sat 24 Mar 2018 08:41:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:9300 Sat 24 Mar 2018 08:41:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8241 Sat 24 Mar 2018 08:40:41 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:9360 Sat 24 Mar 2018 08:36:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:9358 Sat 24 Mar 2018 08:36:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:9359 Sat 24 Mar 2018 08:36:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:9508 Sat 24 Mar 2018 08:35:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:9324 Sat 24 Mar 2018 08:33:54 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:9325 Sat 24 Mar 2018 08:33:54 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13657 s) was similar across all sites. The familial recurrence risk of MS in Australia is lower than in previously reported studies. This is directly related to the lower population prevalence of MS. The overall genetic susceptibility in Australia as measured by the λ_s is similar to the northern hemisphere, suggesting that the difference in population risk is explained largely by environmental factors rather than by genetic admixture.]]> Sat 24 Mar 2018 08:25:18 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14142 Sat 24 Mar 2018 08:24:51 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14315 Sat 24 Mar 2018 08:24:40 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14711 Sat 24 Mar 2018 08:19:11 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15473 Sat 24 Mar 2018 08:19:03 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12950 1) between patient cohorts receiving specialised care for different lengths of time. Results: Improved mean height z-score (−0.880 v −0.047) and weight centile (28.3% v 48.1%) for the 10–15 year age group in 1997, who had received continuous lifetime care within the clinic, compared with the same age group in 1993, for whom continuous medical care started at an older age. There was no corresponding improvement in FEV₁, as an indicator of lung function, in this group (81.6% predicted v 89.5% predicted). Conclusions: This study suggests that lifetime continuous care within a specialised CF centre is associated with improved growth but not improved lung function.]]> Sat 24 Mar 2018 08:18:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12770 Sat 24 Mar 2018 08:18:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20930 Sat 24 Mar 2018 08:06:04 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18137 Sat 24 Mar 2018 08:04:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17515 Sat 24 Mar 2018 08:03:51 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:16528 Sat 24 Mar 2018 08:01:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21154 Sat 24 Mar 2018 08:00:18 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21800 Haemophilus influenzae is one of the most commonly isolated bacteria. The relationship between chronic airway colonisation and the development of steroid-resistant neutrophilic asthma is unclear. Objectives: To investigate the relationship between H influenzae respiratory infection and neutrophilic asthma using mouse models of infection and ovalbumin (OVA)-induced allergic airways disease. Methods: BALB/c mice were intratracheally infected with H influenzae (day 10), intraperitoneally sensitised (day 0) and intranasally challenged (day 12–15) with OVA. Treatment groups were administered dexamethasone intranasally during OVA challenge. Infection, allergic airways disease, steroid sensitivity and immune responses were assessed (days 11, 16 and 21). Results: The combination of H influenzae infection and allergic airways disease resulted in chronic lung infection that was detected on days 11, 16 and 21 (21, 26 and 31 days after infection). Neutrophilic allergic airways disease and T helper 17 cell development were induced, which did not require active infection. Importantly, all features of neutrophilic allergic airways disease were steroid resistant. Toll-like receptor 4 expression and activation of phagocytes was reduced, but most significantly the influx and/or development of phagocytosing neutrophils and macrophages into the airways was inhibited. Conclusions: The combination of infection and allergic airways disease promotes bacterial persistence, leading to the development of a phenotype similar to steroid-resistant neutrophilic asthma and which may result from dysfunction in innate immune cells. This indicates that targeting bacterial infection in steroid-resistant asthma may have therapeutic benefit.]]> Sat 24 Mar 2018 07:59:21 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17739 Sat 24 Mar 2018 07:57:38 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17903 Sat 24 Mar 2018 07:56:40 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17993 24 h of life. Data sources: MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, CINAHL, Cochrane Library, clinicaltrials.gov, controlled-trials.com, American Pediatric and European Paediatric Research Societies and Effective Care of the Newborn Infant. Review methods: ystematic review with network meta-analysis of randomised studies comparing intravenous indomethacin, ibuprofen or placebo for PDA in preterm infants at >24 h of life. Results: ten trials compared intravenous indomethacin versus intravenous ibuprofen, nine intravenous indomethacin versus placebo and one intravenous ibuprofen versus placebo. Both intravenous indomethacin (pooled RR 2.39 (95% CI 2.05 to 2.78)) and intravenous ibuprofen (RR 2.40 (95% CI 2.03 to 2.84)) closed a PDA more effectively than placebo. Intravenous ibuprofen was associated with approximately 30% greater risk of chronic lung disease than intravenous indomethacin (RR 1.28 (95% CI 1.03 to 1.60)) or placebo (RR 1.29 (95% CI 0.99 to 1.70)). Differences in risk or benefit were not significant between any combination of intravenous indomethacin, intravenous ibuprofen or placebo groups for intraventricular haemorrhage, necrotising enterocolitis and death. Reporting on neurological outcomes was insufficient for pooling. Conclusions: intravenous indomethacin or ibuprofen administered to preterm infants for PDA at >24 h of life promoted ductal closure, but other short-term benefits were not seen. Treatment with intravenous ibuprofen may increase the risk of chronic lung disease. Good-quality evidence of treatment effect on morbidity, mortality and improved neurodevelopment is urgently needed.]]> Sat 24 Mar 2018 07:56:35 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17886 Sat 24 Mar 2018 07:56:18 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21251 Sat 24 Mar 2018 07:54:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19328 Sat 24 Mar 2018 07:52:14 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28283 Sat 24 Mar 2018 07:41:21 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28472 2 than ≤2. Two-point progression was uncommon for EDSS score of <2 and more common at EDSS score of 4. Conclusions: EDSS rank stability increases with disease duration, probably due to reduced relapses and less random variation in later disease. After 4 years duration, EDSS rank was highly predictive of EDSS rank 5 years later. Risk of progression by 10 years was highly dependent on EDSS score at 5 years duration. We confirm the utility of EDSS ranking to predict 5-year outcome in individuals 4 years after disease onset.]]> Sat 24 Mar 2018 07:39:35 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28742 Sat 24 Mar 2018 07:37:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26934 KDELR2 (KDEL endoplasmic reticulum protein retention receptor 2) and GRID2IP (glutamate receptor, ionotropic, delta 2 (Grid2) interacting protein), showed consistent IBS risk effects in the index GWAS and all replication cohorts and reached p=9.31×10^-6 in a meta-analysis of all datasets. Several SNPs in this region are associated with cis effects on KDELR2 expression, and a trend for increased mucosal KDLER2 mRNA expression was observed in IBS cases compared with controls. Conclusions: Our results demonstrate that general population-based studies combined with analyses of patient cohorts provide good opportunities for gene discovery in IBS. The 7p22.1 and other risk signals detected in this study constitute a good starting platform for hypothesis testing in future functional investigations.]]> Sat 24 Mar 2018 07:27:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26941 Sat 24 Mar 2018 07:27:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26464 Sat 24 Mar 2018 07:27:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26978 Sat 24 Mar 2018 07:26:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25354 Sat 24 Mar 2018 07:24:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26238 Sat 24 Mar 2018 07:24:05 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22584 Sat 24 Mar 2018 07:15:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22009 Chlamydia and Haemophilus lung infection-induced SSIAAD. We used these models to investigate the effects of clarithromycin and amoxicillin treatment on immune responses and airways hyper-responsiveness (AHR) in Ova-induced, T helper lymphocyte (Th) 2 -associated steroid-sensitive AAD and infection-induced Th1/Th17-associated SSIAAD compared with dexamethasone treatment. Results: Clarithromycin and amoxicillin had similar antimicrobial effects on infection. Amoxicillin did attenuate some features, but did not broadly suppress either form of AAD. It did restore steroid sensitivity in SSIAAD by reducing infection. In contrast, clarithromycin alone widely suppressed inflammation and AHR in both steroid-sensitive AAD and SSIAAD. This occurred through reductions in Th2 responses that drive steroid-sensitive eosinophilic AAD and tumour necrosis factor a and interleukin 17 responses that induce SSIAAD. Conclusions: Macrolides have broad anti-inflammatory effects in AAD that are likely independent of their antimicrobial effects. The specific responses that are suppressed are dependent upon the responses that dominate during AAD.]]> Sat 24 Mar 2018 07:15:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24277 Sat 24 Mar 2018 07:14:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23677 Sat 24 Mar 2018 07:13:57 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24195 Sat 24 Mar 2018 07:12:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24614 T, p.Q301*). The mutation segregated with the disease in the family and was not observed in over 100 000 control X chromosomes. The mutation markedly reduced RNF113A protein expression in extracts from lymphoblastoid cell lines derived from the affected individuals. Conclusions: The association of RNF113A mutation with non-photosensitive TTD identifies a new locus for these disorders on the X chromosome. The extended phenotype within this family includes panhypopituitarism, cutis marmorata and congenital short oesophagus.]]> Sat 24 Mar 2018 07:11:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22633 Sat 24 Mar 2018 07:11:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22105 Sat 24 Mar 2018 07:10:20 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34153 Mon 23 Sep 2019 13:38:24 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18663 Mon 20 Jul 2015 17:06:14 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27244 Mon 09 Oct 2023 14:51:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27990 Mon 09 Oct 2023 14:51:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21756 Fri 10 Mar 2023 19:13:35 AEDT ]]>